<DOC>
	<DOC>NCT00133172</DOC>
	<brief_summary>The purpose of this study is to compare the safety and efficacy of a tacrolimus-based 5-day steroid rapid withdrawal immunoprophylactic regimen in de novo renal transplantation.</brief_summary>
	<brief_title>Effect of Rapid Steroid Withdrawal on Subclinical Markers of Rejection</brief_title>
	<detailed_description />
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Subject or legally acceptable guardian has signed and dated a Research Ethics Board (REB)approved informed consent form and is willing and able to follow study procedures. Subject is the recipient of a first or second cadaveric or living donor mismatched (at least one mismatch) renal transplant. Subject is 18 years of age or over at the time of transplant. If female and of childbearing potential, subject has a negative pregnancy test and utilizes adequate contraceptive methods Recipients of a kidney from a donor 60 years of age or older Recipients of donation after cardiac death (DCD) donors Recipients of a combined transplant (e.g. kidneypancreas, lung, heart) Subjects with a second renal allograft who had their original graft for &lt; 2 years, unless the initial graft was lost in the early (1 year or less) post transplant course due to a technical or surgical failure Subjects with a current/latest pretransplant panel of reactive antibodies (PRA) &gt;20 Subjects with hepatitis B &amp; C, HIV or cancer (excluding successfully excised squamous or basal cell carcinoma) Subjects receiving an allograft with cold ischemia time 24 hours or greater Subjects who have received an investigational drug within three months prior to randomization Subjects who are breastfeeding Subjects with known hypersensitivity to tacrolimus, mycophenolate mofetil, methylprednisolone, basiliximab, prednisone, or any related drugs or their excipients Subjects with significant disease (e.g. uncontrolled infection) or disability (e.g. cognitive deficit) that prevents understanding of or adherence to the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Treatment Efficacy</keyword>
	<keyword>Treatment Effectiveness</keyword>
	<keyword>Anti-rejection therapy</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Antirejection</keyword>
	<keyword>Renal Transplantation</keyword>
	<keyword>Transplantation, Renal</keyword>
	<keyword>Transplantation, Kidney</keyword>
	<keyword>Grafting, Kidney</keyword>
</DOC>